Drug Monograph

Drug Name: **Dupixent® (dupilumab) pen**
Drug Class: **Respiratory: Monoclonal Antibodies**
Prepared For: MO HealthNet
Prepared By: Conduent

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Dupixent is now available in a 200 mg/1.14 ml single-use pre-filled pen. It was previously available in a 300 mg/2 ml single-dose pre-filled pen and 300 mg/2 ml and 200 mg/1.14 ml single-dose pre-filled syringes with needle shields.
Manufacturer:	Manufactured by: Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591.
Indications:	Dupixent is indicated: 1) for the treatment of patients ≥ 6 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable (Dupixent can be used with topical steroids), 2) as an add on maintenance treatment in patients with moderate-to-severe asthma ≥ 12 years with an eosinophilic phenotype or with oral corticosteroid dependent asthma, 3) as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).
Costs:	$1601.69 per pen or $3203.39 per month. Wholesale Acquisition Cost
Summary of Findings:	This drug is being considered for inclusion in the state specific Preferred Drug List as non-preferred.
Status Recommendation:	☐ Clinical Edit ☐ PA Required ☐ Open Access ☒ PDL
Type of PA Criteria:	☐ Appropriate Indications ☒ Non-Preferred ☐ No PA Required ☐ Preferred

Prepared by: April Ash, PharmD
Date: July 30, 2021